David M. Lubaroff, PhD Founder and Chief Scientific Officer OHANA VACCINES, LLC Partnering for Growth March 2018 David M. Lubaroff, PhD Founder and Chief Scientific Officer Ohana Vaccines, LLC

The Problem: Prostate Cancer is a Killer 1,110,000 Globally there are 1.11 M new cases and 307,000 deaths. In 2018, 164,690 men in the US will be diagnosed with prostate cancer and greater than 29,000 will die. 164,690 ~ 30% After initial treatment, about 20-30% of men will show signs of cancer recurrence. There is no cure for recurrent prostate cancer Ohana Vaccines, LLC

Immunotherapy is the New Solution Treatments Immunotherapy is the New Solution Immunotherapies only destroy tumor cells and have no effect on normal cells. Current treatments for recurrent prostate cancer may extend survival, but eventually the cancer continues to grow, resulting in death. All of the treatments are accompanied by significant side effects, reducing the patient’s quality of life. Ohana Vaccines, LLC

How Does Ohana Vaccines, LLC Contribute to the Solution? Use a proprietary & unique combination of safe, non-replicating virus vaccines to target antigens associated with prostate cancer. The “prime-boost” strategy caused the destruction of established prostate cancers in pre-clinical studies. Produce & test vaccines that target multiple prostate cancer-associated antigens Use combinations of vaccine immunotherapy with checkpoint inhibitors. Ohana Vaccines, LLC

Anti-Prostate Cancer Vaccines What Does Ohana Vaccines, LLC do? A pharmaceutical company that develops… Anti-Prostate Cancer Vaccines ‘Off-the-Shelf’ Therapeutic Vaccines Cure or extend life greater than currently observed, all without serious side effects Ohana Vaccines, LLC

Immunotherapeutic Vaccines by Ohana Vaccines. LLC Ohana aims to cure recurrent prostate cancer - without significant side effects. Ohana employs a “prime-boost” strategy with proven efficiency in preclinical studies. The priming vaccine has been tested in preclinical and clinical studies. Ohana Vaccines, LLC

Market Opportunity of Recurrent Prostate Cancer Total cost $175B for cancer treatment in 2020 Prostate cancer/ all cancer 10.7% prostate cancer in the US Target: recurrent prostate cancer In the US 20-30 % recurrence Market : Global $175 B US Market : $18.7 B Target : up to $5.62 B Hospitalizations alone were estimated to cost $1.9 B in the US and $13.64 B globally. https://seer.cancer.gov https://www.cancer.org Future Oncol, 2015; 11 (3):439-447 Ohana Vaccines, LLC

Ohana Vaccines, LLC Milestones FDA Open to Single Pivotal Combined Phase I/II Trial (2018) Raising Seed Capital to complete Phase I/II Trial Additional Clinical Trials and/or Exit (2019) Phase I & II Trials for both adenovirus and Phase I for alphavirus vaccines completed successfully A Provisional Patent application was submitted on April 19, 2017 Ohana Vaccines, LLC

Ohana Vaccines, LLC Generates Promising Results in Fighting Prostate Cancer Both vaccines that will be used in the Prime-Boost protocol were safe in the previous Phase I and Phase II clinical studies Ohana vaccines priming vaccine caused the induction of immune responses and clinical benefits In the new preclinical studies, the booster vaccine demonstrated the ability to induce antigen-specific immune responses Ohana’s Prime-Boost protocol induced the highest level of anti-PSA immune responses and destroyed established tumors in 100% of the vaccinated mice. Ohana Vaccines, LLC

The Company Management Team: Hank Harris, DVM, PhD - CEO Matthew Lubaroff MBA - COO David M Lubaroff, PhD - Founder & CSO Mark Ehrmann, JD, - legal and patents Advisory Board: George Weiner, MD Gail Bishop, PhD Wendy Maury, PhD Joel Harris, BA Adam Koppes, JD Mark Ehrmann, JD

Thank You Questions?